Teva and Active Biotech Announce CONCERTO trial of Laquinimod in RRMS Did Not Meet Primary Endpoint


The primary endpoint in CONCERTO -- the evaluation of laquinimod versus placebo to evaluate the time to Confirmed Disability Progression after at least 3 months - was not met. . Other data details announced by the Company show that on the secondary endpoint which measured change in brain volume-- an indicator of disability progression over time-- compared to baseline was positive .



from Biotech News